Navigation Links
Theravalues Confirms Beneficial Effects of Theracurmin™ on Diastolic Function in Hypertensive Patients
Date:11/10/2011

ORLANDO, Fla., Nov. 10, 2011 /PRNewswire/ -- Theravalues, a Japan based bio-venture, announced today that Theracurmin™, its curcumin-based product, impacts positively on the prevention of heart failure and its progression for the first time in history. During the human clinical trial started with the registration in July 2010, conducted by the company with National Hospital Organization Kyoto Medical Center and University of Shizuoka, Japan, the researchers found that Theracurmin™, which is absorbed by the body at a rate 27 times higher than curcumin powder, could effectively prevent diastolic failure.

(Logo:  http://photos.prnewswire.com/prnh/20111110/FL04434LOGO)

Dr. Tatsuya Morimoto, Professor at the Division of Molecular Medicine School of Pharmaceutical Sciences, at the University of Shizuoka said, "We are extremely excited to discover that Theracurmin™ has positive effects in curbing left ventricular diastolic failure at a statistically significant level." In the 24-week human trial, Theracurmin™, the absorption-enhanced curcumin invented by Theravalues, was prescribed for 30 subjects with left ventricular diastolic failure and their symptoms improved significantly. "The result of the study encourages patients and the elderly who have been suffering chronic cardiac problems," he added.

Curcumin, a polyphenol derived from turmeric (Curcuma Longa L,) has anti-inflammatory and anti-oxidant therapeutic properties. These properties effectively treat chronic inflammatory diseases. However, it has poor bioavailability due to its low oral absorption. Through Theracurmin™, Theravalues invented an innovative technology to solve this problem by creating surface controlled colloidal dispersion.

The FDA has approved Theracurmin™ for clinical trial in the United States. Last month, The University of Texas MD Anderson Cancer Center began treatment of malignant tumors caused by progressive cancer with Theracurmin™.

Mr. Hashimoto, the Representative Director and President of Theravalues said, "Theracurmin™ brings several exciting avenues of opportunity. We are confident about the potential power of Theracurmin™ not only for heart failure, but also for many incurable diseases and the maintenance of wellness of the people around the globe."

"While we were fascinated by the versatility of curcumin to help treat many diseases, its low oral absorption was the greatest challenge. Theracurmin™ improved the absorption of curcumin, making it 27 times higher than curcumin powder," said Dr. Koji Hasegawa, Director of the Division of Translational Research at National Hospital Organization Kyoto Medical Center. "In addition to its effectiveness on diastolic failure, we have been studying other application of Theracurmin™ to broaden its application into cancers, hepatic functions, skin conditions, ALS and Alzheimer's disease," he continued.

ABOUT THERAVALUES CORPORATION

Founded in 2007, Japan-based Theravalues Corporation strives to deliver better physical and mental health which gives much satisfaction to people around the world. Theravalues creates value through innovation, developing foods, medicines and technological models that achieve high satisfaction and healthy lives.

Learn more at www.theravalues.com/english  

Contact: Masami Hasegawa (Theravalues, Japan)
+81.3.3234.7677
mhasegawa@theravalues.com


'/>"/>
SOURCE Theravalues Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
3. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
4. Mylan Confirms Four First-to-File Challenges
5. GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
6. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
7. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
8. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
9. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
10. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
11. Analysis confirms that nano-related research has strong multidisciplinary roots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... of the QB3@953 life sciences incubator to ... health. The shared laboratory space at QB3@953 was created ... a key obstacle for many early stage organizations - ... of the sponsorship, Amgen launched two "Amgen Golden Ticket" ...
(Date:6/22/2016)... 22, 2016 Research and Markets has announced ... report to their offering. ... from $29.3 billion in 2013. The market is expected to grow ... 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 ... during the forecast period (2015 to 2020) are discussed. As well, ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):